TherapeuticsMD submits NDA for TX-001HR to treat menopause symptoms

TherapeuticsMD Inc. (NYSE-M:TXMD) submitted an NDA to FDA for TX-001HR estradiol/progesterone to treat moderate to severe vasomotor symptoms due to menopause. The candidate is an oral combination caps...